Sample data gathering tool for patients with recent/new hepatitis B or C virus infection without known risk factors for viral hepatitis to help guide health departments in identifying potential healthcare exposures that may warrant further public health investigation

Instructions: Gather available clinical and diagnostic data in Part 1 on pages 1-3. Use these data to calculate possible exposure period using guidance in Part 2 on pages 4-6. This time window may be used during the patient interview in Part 3 pages 7-16.

Part 1: Clinical and Diagnostic Data

Note: Clinical and Diagnostic Information may be transferred from the state department of health acute hepatitis case report form, and/or you may wish to review symptoms and dates with case patient during interview.

| DATE laboratory report was received | at Local Health D | epartment / / | |
|--|-------------------|----------------------|---------|
| (record results in next section) | | | |
| REASON FOR TESTING: (Check a | ll that apply) | | |
| Symptoms of acute hepatitis | Blood / or | rgan donor screening | Unknown |
| Evaluate elevated liver enzymes | | | |
| Screening of asymptomatic patient | | | |
| | | | |
| DIAGNOSIS: (Check all that apply) | | | |
| Hepatitis B: acutechror | icunknown | | |
| Hepatitis C: acutechro | nicunknown | ı | |
| CLINICAL DATA: | | | |
| Diagnosis date:/// | | | |
| a. Was patient symptomatic? Y | es No | _ Unk | ::// |
| b. Was patient jaundiced? Y | es No | _ Unk | ::// |
| c. Did the patient experience: | | | |
| Loss of appetite Yes | No Un | k | |

| Nausea | Yes | No _ | Unk |
|----------------|---------------|-------------|----------------------------------|
| Vomiting | Yes | No _ | Unk |
| Abdominal Pain | Yes | No _ | Unk |
| Fever | Yes | No _ | Unk |
| Dark Urine | Yes | No _ | Unk |
| Other, specify | | | _ |
| • | - | • | YesNoUnk discharge date*: / / |
| Did patient di | e during adm | nission? | yesnounk |
| | If, yes, date | of death: _ | /// |

Diagnostic tests. Check all that apply. If tested on more than one date record all test results and dates through (including) date of first positive test.

Note: Creating a spreadsheet to depict evolving serology over time may be particularly useful for hepatitis B (sample attached at end of document).

| Hepatitis B surface a | intigen [HBsAg] | | Pos Pos | NegUnk NegUnk | Date(s): Date(s): | / / |
|-----------------------|----------------------------------|------------|------------|------------------|----------------------|------------|
| Total antibody to hep | patitis B core antigen [total an | ti-HBc] | Pos | NegUnk NegUnk | Date(s): Date(s): | <u> </u> |
| IgM antibody to hep | atitis B core antigen [IgM anti | i-HBc] | Pos Pos | NegUnk NegUnk | Date(s): Date(s): | <u> </u> |
| HBV DNA | | | Pos | NegUnk NegUnk | Date(s): Date(s): | / / / / |
| If positive, (spec | ify viral load(s) if available _ | | | | | |
| HBV Genotype resul | lt, if tested | | | | Date:/_ | / |
| Antibody to hepatitis | s C virus [anti-HCV] | | Pos Pos | NegUnk NegUnk | Date(s): Date(s): | / / |
| HCV RNA | | | Pos | NegUnk NegUnk | Date(s): Date(s): | <u> </u> |
| If positive, speci | fy viral load(s) if available | | | _ | | |
| HCV Genotype resul | lt, if tested | | | | Date:/_ | / |
| Antibody to hepatitis | s D virus [anti-HDV] | | Pos | NegUnk | Date(s): | |
| ALT [SGPT] Result | ELS AT TIME OF DIAGNO | Date _ | | | | |
| AST [SGOT] Result | Upper limit normal | Date _ | /_ | / | _ | |
| if known PRIOR LIVE | R ENZYME LEVELS, with | baseline a | nd first | elevated level(s | s) | |
| ALT [SGPT] Result | Upper limit normal | Date _ | /_ | / | _ | |
| AST [SGOT] Result | Upper limit normal | Date _ | /_ | / | _ | |
| ALT [SGPT] Result | Upper limit normal | Date _ | /_ | / | _ | |
| AST [SGOT] Result | Upper limit normal | Date | / | / | | |


Part 2. Determining likely time period of HBV/HCV exposure (exposure window) based on laboratory and clinical findings

Note: This general guidance may not encompass all possible scenarios. CDC Division of Viral Hepatitis staff are always available for consultation at viralhepatitisoutbreak@cdc.gov or CDC-INFO 1-800-232-4636 (ask for Division of Viral hepatitis subject matter expert) See: https://www.cdc.gov/hepatitis/contactus.htm


1. For patients with a history of negative nucleic acid tests (NAT) or serology (for HBV, HBsAg and/or total anti-HBc; for HCV, anti-HCV) prior to the recent positive test:

| Note: On average about 3 weeks (possibly up to 12 weeks) m detectability, up to 6 months before anti-HCV seroconversion HCV RNA detectability. | |
|---|--------------------------------------|
| See: https://www.cdc.gov/hepatitis/outbreaks/toolkit.htm | |
| a. fill in date(s) and type(s) of most recent negative test(s). In Date(s) _ / _ / _ Date(s) _ / _ / Date(s) _ / _ / Date(s) _ / _ / Date(s) _ / _ / | clude all serologic and NAT results. |
| b. fill in date(s) and type(s) of <u>first positive test(s)</u> . Include a | all serologic and NAT results. |
| Date(s)/_/ Date(s)/_/ Date(s)/_/ Date(s)/_/ Date(s)/_/ | |
| c. The possible HBV exposure window may be estimated us about three weeks (typical range 1-9 weeks, possibly up to 12 HBsAg/HBV DNA detectability. | |
| On average about 3 weeks from exposure to NAT+, possibly up to 12 weeks Date of last negative HBV DNA | Date of first positive HBV DNA |
| | |
| Possible exposure window based | on HBV DNA or HBsAg tests |
| Likely exposure window: _ | / to/ |

d. The **possible HCV exposure window** may be estimated using NAT for HCV RNA and/or anti-HCV tests. For NAT on average the exposure may have been as early as one-two weeks prior to the last negative HCV NAT result, through one-two weeks before the first positive HCV RNA result. Using anti-HCV results the exposure may have been as early as 6 months prior to the last negative anti-HCV result through eight to 11 weeks prior to the <u>first</u> positive anti-HCV result.



e. Elevations in liver function tests when serial testing available, if noted and not clearly ascribed to other clinical comorbidites, may help to define the most likely time of exposure within the window defined by other lab tests. For HBV average time from exposure to <u>first</u> elevation is two months, range 40-90 days. For HCV the average time to first elevation can be as early as 2 weeks, degree and duration of ALT may be variable.



| - | and symptoms: | s/symptoms such as jaundice Date// |
|------------------------------------|---|---|
| For HBV the average | ge onset of signs/sympton | oms (when present) is at 12 weeks after exposure, with a <u>range of 9-21 wee</u> |
| | | |
| 21 weeks prior to symptom onset | 9 weeks prior to symptom onset 12 weeks prior to symptom onset Date of symptom on symptom onset | onset. |
| | gment of HBV exposur | |
| | window:// ge onset of symptoms (w | when present) is 6-7 weeks after exposure with a <u>range of 2-26 weeks</u> . |
| | | |
| 26 weeks prior to symptom onset | 2 weeks prior to symptom onset 6-7 weeks prior to symptom Onset Date of symptom or onset | onset. |
| | | |
| | gment of HCV exposure et of symptoms, when | |
| Likely exposure win | ndow:/ to | // |
| | | |

a. While an exact exposure window cannot be determined, recent potential healthcare exposures over a period of some months may be taken into consideration to determine possible times when exposure may have occurred that are most

feasible for investigation.

Worksheet summarizing guidance for determining possible exposure window for persons with new HBV diagnosis

| Options to Estimate First Date of Incubation Period | 1) Fill in the Date of Test: | 2) Subtract: | 3) Equals Estimated First Date of Incubation Period | Options to Estimate Last Date of Incubation Period | 4) Fill in the Date of Test: | 5) Subtract: | 6) Equals Estimated Last Date of Incubation Period |
|--|------------------------------------|--------------|--|---|---------------------------------|-----------------|--|
| Last negative HBV DNA | | 12 weeks | | First positive HBV DNA | | 1-3 weeks | |
| Last negative HBsAg | | 12 weeks | | First positive HBsAg | | 1-3 weeks | |
| First elevation in ALT* | | 3 months | | First elevation in ALT* | | 6 weeks | |
| Onset of symptoms | | 21 weeks | | Onset of symptoms | | 9 weeks | |
| Single positive HBV DNA or HBsAg and no symptoms or prior test results | | 1 year^ | | | | | |
| Summary Date(s): | | | | Summary Date(s): | | | |

^{*}This assumes that serial ALT levels are collected in an ongoing fashion.

[^] This recommendation should be considered in the context of all available evidence. If no other data are available, this is a reasonable option.

| Options to estimate first date of exposure window | 1) Fill in the date of test: | 2) Subtract: | 3) Equals estimated first date of exposure window | Options to estimate last date of exposure window | 4) Fill in the date of test: | 5) Subtract: | 6) Equals estimated last date of exposure window |
|---|------------------------------------|--------------|---|--|------------------------------------|-----------------|--|
| Last negative HCV RNA | | 1-2 weeks | | First positive HCV RNA | | 1-2 weeks | |
| Last negative anti-HCV | | 6 months | | First positive anti-HCV | | 8 weeks | |
| | | | | First elevation in ALT* | | 2 weeks | |
| Onset of symptoms | | 26 weeks | | Onset of symptoms | | 2 weeks | |
| Single positive HCV RNA or anti-HCV and no symptoms or prior test results | | 1 year^ | | | | | |
| Summary Date(s): | | | • | Summary Date(s): | | | • |

^{*}This assumes that serial ALT levels are collected in an ongoing fashion.

[^] This recommendation should be considered in the context of all available evidence. If no other data are available, this is a reasonable option.

References

- 1. CDC. Healthcare notification and testing toolkit. Bloodborne Pathogens Testing. https://www.cdc.gov/hepatitis/outbreaks/toolkit.htm Accessed November 26, 2018.
- 2. CDC. Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection. Morb Mortal Wkly Rpts 2008, 57 (RR08). https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm
- 3. CDC. Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. Morb Mortal Wkly Rpts 1998, 47 (RR19). http://www.cdc.gov/mmwr/PDF/RR/RR4719.pdf
- 4. CDC. Viral Hepatitis Serology training: https://www.cdc.gov/hepatitis/resources/healthprofessionaltools.htm Accessed 11/26/2018.
- 5. Association of Public Health Laboratories. Interpretation of Hepatitis C Virus Test Results: Guidance for Laboratories: https://www.aphl.org/aboutAPHL/publications/Documents/ID-2019Jan-HCV-Test-Result-Interpretation-Guide.pdf Accessed 1/28/2019.

Note that persons with past resolved HBV (HBsAg negative, total anti-HBc positive) or occult HBV infection (intermittent HBsAg positive with low-level or undetectable HBV DNA measurements; total anti-HBc positive) may reactivate to active HBV replication during periods of substantial immune compromise https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm

Part 3. Sample PATIENT INTERVIEW

Note: questions for internal health department use only

| Date Interview Completed (mm/dd/ | yy):/_ | / Interviewer |
|----------------------------------|--------------------|----------------------|
|] | DEMOGRAPHIC | CINFORMATION |
| PRIMARY RESIDENCE: State: _ | C | county: |
| DACE (shoots all that apply) | | |
| RACE (check all that apply): | A | Other Beer weekfin |
| American Indian/Alaska Native | | Other Race, specify: |
| Black or African American | Pacific Islander | an or Other |
| White | Pacific Islander | |
| ETHNICITY: Hispanic, Latino/a | or Spanish origin? | Ves No Unk |
| ETHINETTT. Hispanic, Latino, a | or spanish origin. | |
| SEX: Male Female | Unk | |
| | | |
| PLACE OF BIRTH:USA | Other, spec | ify: |
| | , - F | |
| DOB:// | AGE: | (years) |
| | | |
| MEDICAL INSURANCE: | | |
| Private Insurance | Medicaid | Refused |
| HMO | Medicare | Unknown |
| Military | Uninsured | |
| | | |
| OCCUPATION/SETTING: | | |
| Food Service | Student/School | olUnknown |
| Day Care | Corrections W | Vorks |
| Health Care | Other Occupa | tion, specify: |

PATIENT HISTORY

Note: encourage participants to have a calendar in front of them during the interview, and to gather other relevant paperwork, such as an appointment calendar, insurance statements, canceled checks or credit card statements. Some physicians also send email and text reminders for appointments and they may supply discharge instructions or after care instructions with a signature and date. Pill bottles will have date of prescription and might provide memory prompts if a prescription was written at the time of a procedure. Dates of holidays (July 4, Memorial Day, Thanksgiving ...) can also serve as memory prompts. Some physicians also have an electronic patient portal that may provide information on dates of procedures. Informal date estimates may be checked against medical records.

| 1. | Before your recent illness were you ever diagnosed with hepatitis? | Yes | No | Unk |
|----|--|---------------|----------|---------|
| | a. If yes, do you recall approximately when this occurred or what type of hep | atitis it was | (prompt: | A, B, C |
| | serum, infectious, autoimmune): type year | | | |
| | If yes for hepatitis B or C: Did you develop chronic infection? | Yes | No | Unk |
| | b. If no, did you ever have an illness marked by jaundice (yellowing of the sk | in or eyes): | ? | |
| | | Yes | No | Unk |
| 2. | Have you tried to donate blood any time since 1970? | Yes | No | Unk |
| | If yes, (specify most recent year) | | | |
| | a. If yes, were you ever told that your blood could not be accepted or used? | Ves | No | Unk |
| | If yes, please specify reason: | | | |
| 3. | Did you ever receive hepatitis B vaccine? | Yes | No | Unk |
| | If yes, how many shots?123+ | | | |
| | When was the last shot received?/ | | | |
| 4. | a. Do you have difficulty dressing, bathing, or getting around inside the home | e? | | |
| | | Yes | No | Unk |
| | b. Do you have difficulty going outside the home alone to shop or visit a doct | tor's office? | ? | |
| | | Yes | No | Unk |
| | | | | |

| Read to patient: "For the remaining questions, the time period we are interested window, that is, the period between (fill in estimated dates)/ and | | • | xposure |
|---|------------|--------------|----------|
| | | | |
| 5. During the exposure window were you a contact of a person who you were awar | e had acu | ite or chro | onic |
| hepatitis B or hepatitis C virus infection? | | | |
| YesNoUnk | | | |
| If yes, specify type of contact: | | | |
| Hepatitis B Hepatitis C hepatitis of unknown ty | pe | | |
| Household [Non-sexual]: Yes No Unk | • | | |
| Sexual:YesNoUnk | | | |
| Other: | | | |
| | | | |
| 6. During the exposure window did you: | | | |
| a. Receive a tattoo or body piercing? | Yes | No | Unk |
| If yes, specify location (for example, commercial tattoo parlor, prison, from | n a friend | , at a tatto | oo or |
| piercing party): | | | |
| b. Travel outside the United States or Canada? | Yes | No | Unk |
| If Yes, specify locations (Country) and approximate dates: | | | |
| 1) from/ to/ | | | |
| 2) from// to// | | | |
| 3) from// to// | | | |
| c. Work in a medical field involving contact with human blood or body flu | ids? | | |
| _ | Yes | No | Unk |
| d. Work in a dental field involving contact with human blood or body fluid | ls? | | |
| _ | Yes | No | Unk |
| e. Work in any other setting where you possibly could have had contact wi | th human | blood or | body |
| fluids? | Yes | No | Unk |
| If yes, specify setting: | | | |
| If yes, specify body fluid: | | | |
| f. Have an accidental stick or puncture with a needle or other object possib | ly contan | ninated wi | th human |
| blood or body fluids? | Yes | No | Unk |
| If yes, specify the date:/, setting: | | | |
| If yes, specify body fluid: | | | |

| g. Reside (live in) a long term care facility? | Yes | No | Unk |
|---|---------------------|---------|-----|
| If yes, for how long | | | |
| h. Receive medical care in your home from visiting nurses or cert | ified health profes | sional? | |
| | Yes | No | Unk |
| If yes, specify: | | | |
| 1. Type of care provided | | | |
| Frequency: times/month or times/week | ζ | | |
| 2. Type of care provided | | | |
| Frequency:times/month or times | nes/week | | |
| 3. Type of care provided | | | |
| Frequency: times/month or times | nes/week | | |
| 4. Type of care provided | | | |
| Frequency: times/month or times | mes/week | | |
| | | | |
| i. Receive medical care in your home from relatives or other person | ons?Yes | No | Unk |
| If yes, specify and include dates on healthcare exposure t | table, final page: | | |
| 1. Type of care provided | | | |
| Frequency: times/month or times | nes/week | | |
| 2. Type of care provided | | | |
| Frequency:times/month or times | nes/week | | |
| 3. Type of care provided | | | |
| Frequency: times/month or times | nes/week | | |
| 4. Type of care provided | | | |
| Frequency: times/month or times | mes/week | | |
| | | | |
| | | | |

7. In the next section, we will review some different types of health care encounters you may have had during the exposure window. (Note: if subject denies any healthcare whatsoever, explain that we still need to take a minute to review the following list because it includes some things that people sometimes don't think of as healthcare. Use explanation of procedure in parenthesis if participant is not familiar with procedure.)

(Check all that apply)

PLEASE INDICATE WHETHER THE TREATMENT WAS RECEIVED AS A HOSPITAL INPATIENT (H), AT AN OUTPATIENT CLINIC (O), OR BOTH

| 1. | Dental work or visit a dentist |
|-----|---|
| 2. | Podiatry care (i.e., did you see a foot doctor)? |
| 3. | Skin care procedure (i.e., from a dermatologist)? |
| 4. | Cosmetic procedure (i.e. from a dermatologist or plastic surgeon)? |
| 5. | Blood sugar [glucose] levels: |
| | If yes, did you share any testing equipment with another person?YesNoUnk |
| | If yes, specify: fingerstick device / lancet / meter / other |
| 6. | Fingerstick for blood donor assessment or any other reason? |
| 7. | Blood tests (i.e., have blood drawn) |
| 8. | Dialysis (Blood is pumped from the body into a filter (dialyzer) where waste products and extra fluid |
| | are removed. The filtered blood is then pumped back into the body) |
| 9. | Apheresis (Blood is pumped from the body and a component of blood is removed from the blood. |
| | The blood is then pumped back into the body) |
| 10. | Flu shot or other vaccines |
| 11. | Shots for arthritis or joint problems |
| 12. | Steroid injections |
| 13. | Injections for pain relief or other treatment at a pain clinic |
| 14. | Allergy injections |
| 15. | Vitamin injections (i.e. B ₁₂) |
| 16. | Care from a traditional healer or herbalist |
| 17. | Injections of any kind not already mentioned |
| 18. | Acupuncture |

| 19. | Chelation therapy (A chemical process in which a synthetic solution—EDTA is injected into the |
|--|--|
| | bloodstream to remove heavy metals and/or minerals from the body (used to treat lead poisoning) |
| 20. | Chemotherapy for cancer treatment |
| 21. | Blood products including transfusion or platelets |
| 22. | Intravenous (IV) fluids or medicines not already mentioned |
| 23. | Radiation therapy |
| 24. | X-rays |
| 25. | Imaging scans (including CAT-scans, PET-scans, MRI) |
| | (CAT scan or Computer axial tomography uses X-rays and computers to produce an image of a |
| | cross-section of the body. Dye may be injected into a vein or taken orally so the radiologist can |
| 20 21 22 23 24 25 26 27 28 29 30 31 32 33 test fo 34 35. | better see the body structures better) |
| | (PET scan or Positron emission tomography is a test that combines computed tomography (CT) and |
| | nuclear scanning. During a PET scan, a radioactive substance called a tracer is combined with a |
| | chemical (such as glucose); this mixture is generally injected into a vein (usually in the arm) but on |
| | occasion may be inhaled.) |
| | (MRI or Magnetic resonance imaging is a test that uses a magnetic field and pulses of radio wave |
| | energy to make pictures of organs and structures inside the body) |
| 26. | Any other imaging exams, specify: |
| 27. | Injected Imaging Dye (From one of the above imaging tests or another imaging test) |
| | Specify: |
| 28. | Vaginal ultrasound (ASK FEMALES ONLY. A technician inserts a sonogram probe into the vagina |
| | and aims sound waves into the pelvic cavity to take pictures of reproductive organs) |
| 29. | Hospital emergency department visit |
| 30. | Hospitalization requiring overnight stay |
| 31. | Anesthesia (Medicine to "put you to sleep" or make you numb to pain during a medical procedure) |
| 32. | Surgery or any operation as inpatient or outpatient |
| 33. | Biopsies as inpatient or outpatient (A small sample of tissue is removed from an area of the body to |
| test j | for cancers or other health conditions) |
| 34. | Wound care |
| 35. | Colonoscopy (Colonoscopy is a test to look at the interior lining of the large intestine via a scope) |
| 36. | Sigmoidoscopy (Similar to a colonoscopy but only shows the rectum and the lower third of the colon) |
| 37. | Other endoscopy (Endoscopy is a nonsurgical procedure used to examine a person's digestive tract) |

| <i>38</i> . L | aparoscopic procedures (Laparoscopy is a surgical procedure that uses a thin, lighted tube called a |
|---------------|---|
| le | aparoscope inserted through an incision in the abdominal wall to examine the abdominal organs or |
| fe | emale pelvic organs) |
| 39. A | arthroscopic procedures (Arthroscopy is a surgical procedure to look at the inside of a joint in the |
| b | ody through a thin viewing instrument called an arthroscope) |
| 40. A | ny other procedure referred to as "scoping" such as cystoscopy and ureteroscopy (A cystoscopy or |
| ur | eteroscopy is a procedure where your physician inserts a flexible scope through your urethra to see |
| in | side your bladder and/or urethra) |
| S | pecify: |
| 41. C | Cardiac catheterization (A thin flexible tube called a catheter is threaded through a blood vessel in |
| у | our arm or groin and into your heart. Through the catheter, your doctor can measure pressures, |
| to | ake blood samples, and inject contrast material into the coronary arteries to trace the movement of |
| b | lood through the arteries) |
| 42. (| Cataract or other eye surgery |
| 43. L | aser procedures, specify: |
| 44. N | ledical procedure or operation not already mentioned |
| Note: If the | respondent answered yes to any of the above, complete the Healthcare Event Table at the end. |
| SENSITIV | VE QUESTIONS: |
| I will now a | sk you several questions that may be of a sensitive nature, but which are important because these |
| activities ca | n explain why some people become infected with hepatitis B or C. Remember that all the |
| information | you share is confidential and you can refuse to answer any of the questions. However it would be |
| | ave a complete response. |
| | |
| 8. During e | xposure window, did you have any sexual partners?YesNoUnk |
| | |
| If Yes, a. I | How many female sex partners did you have? (number of partners) |
| b. | How many male sex partners did you have? (number of partners) |
| ÷. | () |
| 9. During e | xposure window, did you |
| 3 - | |

| Yes | No | Unk |
|-------------|-----------------------------|-----------|
| Yes | No | Unk |
| doctor? | | |
| Yes | No | Unk |
| | | |
| | | |
| ou to someo | ne else's l | olood tha |
| Unk | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | Yes doctor?Yes ou to someou | YesNo |

SAMPLE HEALTHCARE EXPOSURES TABLE

| EVENT or PROCEDURE (cross-ref to listed events from interview) | Address and Telephone of Event Office or Location | START DATE | END DATE | Frequency | Injections | Infusions | Notes |
|--|---|---------------|-------------|----------------------|------------|-----------|-------|
| | | 1 1 | 1 1 | 1 2 3-5 6- 10 10+ | Y N # | Y N # | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

Example spreadsheet for tracking evolving HBV serology and clinical events over time

| Date | 12/21/2017 | 1/4/2018 | 1/9/2018 | 2/23/2018 | 3/12/2018 | 3/14/2018 | 4/3/2018 | 4/9/2018 | 4/13/2018 | 5/6/2018 | 5/23/2018 | 5/30/2018 |
|---|------------------------|---|------------------------|---|-------------------|---|--|--|--------------------------------|--|-------------------|---|
| Location | hospital in state x | outpatient dialysis facility in state x, # patients | 11 | outpatient dialysis facility in state y, # patients | п | u | п | 11 | u | 11 | II. | u |
| Event | First-ever dialysis | | HBV vaccine dose | | | started dialysis in isolation for first time | | | | | | |
| Labs | | HBsAg negative, anti-HBs negative, total anti- HBc negative | | routine monthly HBsAg screen = positive, total anti- HBc negative, | HBsAg positive | HBV DNA = 7676 copies or IU/mL | HBeAg positive, HBsAg positive, HBV DNA positive, total anti- HBc negative | IgM anti- HBc negative | total anti- HBc negative | HBV DNA> 100 e ⁷ , total anti-HBc negative, anti-HBs negative | HBsAg positive | total anti- HBc positive, HBsAg positive, anti-HBs negative |
| Notes (index case age, sex, race, state of residence, other medical conditions) | | | | exposure would have been 1 to 12 weeks prior to this date | | facility screens new pts for HBsAg and anti-HBs; every susceptible screened 2nd Tues each month. Note: no additional cases identified in 6 months of testing. | | appears to have resolved acute IgM by this time | | consistent with evolving acute infection | | consistent with evolving acute infection |